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1. Introduction 
Atherosclerosis is known as a chronic progressive disease with accumulation of 
atherosclerotic plaque inside the vessel wall. Angiography studies revealed small (1-2%) 
increase of lumen during high dose lipid-lowering therapy, but angiography is not the 
appropriate tool for plaque analysis and has many limitations for precise lumen 
measurement due to its projective nature. In contrast, intravascular ultrasound or IVUS can 
accurately measure lumen and vessel diameters, and consequently determine local plaque 
burden. Careful mechanical pullback allows volume measurements of the lumen, vessel and 
plaque over a vessel segment. Serial measurements (baseline and follow-up after several 
months, typically 12±3 months) allow to evaluate changes of these volumes, thus to search 
for plaque progression or plaque regression and assess their mechanisms (for example 
decrease of plaque volume or increase of vessel volume), type of vessel reaction (positive 
and negative remodeling), development of risky plaque features like plaque ulceration and 
plaque ruptures.  
Studies with intravascular ultrasound have shown that disease progression can be stopped 
(GAIN1, REVERSAL2) or reversed (ASTEROID3, ESTABLISH4, COSMOS5), especially in 
response to aggressive lipid-lowering treatment. The mean changes of plaque volume in the 
treated groups were quite small; on the other hand, large scale lipid-lowering trials have 
shown significant reduction of ischemic events. This discrepancy between the clinical 
benefits and the small changes in plaque mass can be explained by plaque stabilization 
(changes of plaque composition from a high risk profile to a low risk profile). However, 
conventional grayscale IVUS has significant limitations in the assessment of plaque 
composition. Virtual histology (VH) based on spectral analysis of IVUS radiofrequency data 
was developed to quantify coronary plaque components6.  
Risk factors for atherosclerosis are same for all coronary arteries, but some regions are more 
affected then others like the proximal third of the arteries, ostial regions, and bifurcations. 
There must be some local factor playing an important role. Local wall shear stress has been 
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identified as such a factor, which is caused by friction between virtual layers of blood inside 
arteries (the velocity of blood flow is maximal in the middle part of arteries and minimal just 
next to the endothelium). Shear stress induces deformation of endothelial cells and activates 
many pro-atherosclerotic genes (VCAM, ICAM, endothelin etc).     
This chapter summarizes results of several aforementioned studies and their impact on 
routine daily practice. Further, it explains how to perform serial IVUS study with precise 
measurement of plaque volume changes and plaque risk feature changes. Second part of 
this chapter is focused on 3D vessel reconstruction based of angiography, IVUS, virtual 
histology and shear stress analysis fusion, which is the technique used for better detailed 
analyses of the atherosclerotic development.     
2. Atherosclerosis 
2.1 Atherosclerosis development 
Atherosclerosis and its complications are the most frequent causes of mortality and 
morbidity in the developed countries. The atherosclerotic research made a great progress in 
investigation of atherosclerosis development, but the regression of atherosclerosis is still a 
process, which is not well understood.  
The best description of atherosclerosis development was proposed by H. Stary et al.7, who 
recognized eight stages of atherosclerotic plaque maturation:   
- type I - initial lesion (adaptive intimal thickening) 
- type II - fatty streaks  (intimal xantomas, intima is infiltrated by macrophages, which 
change their phenotype into  foam cells ) 
- type III - preatheroma (pathologic intimal thickening, lysis of foam cells and 
extracellular accumulation of lipid droplets and lipid pools) 
- type IV - atheroma (formatting of lipid core) 
- type V - fibroatheroma (lipid core is covered by a fibrous cap)  
- type VI - complicated lesion (development of plaque fissures and plaque rupture, 
bleeding to plaque from vasa vasorum ) 
- type VII -  calcified lesion  
- type VIII -  fibrous lesion 
Types I-II are also called initial lesions, types IV and V  developed lesion, type VI is called a 
complicated lesion and types VII and VIII chronic lesions8. This description of atherosclerosis 
development was done by examinations of post mortem specimens from adults and children. 
One of the most important findings is that the atherosclerotic mass is located in the vessel wall, 
and that the lumen area is preserved by positive remodeling up to a specific threshold when 
luminal narrowing starts to occur. This finding was also confirmed in vivo by IVUS9. The 
process of remodeling cannot be observed during coronary angiography, given that only the 
lumen is visualized and its patency is originally retained. While positive remodeling preserves 
the lumen, at the same time it constitutes a risk factor for development of an acute coronary 
syndrome. A likely common pathway is the effect of metalloproteases (enzymes which can 
breakdown collagen). They allow vessel enlargement, but also increase risk of plaque rupture 
due to the decrease of collagen amount inside the plaque10.  
Further morphologic features indicating vulnerable plaque are plaque rupture and higher 
content of necrotic tissue. A very specific type of the rupture-prone plaque is called thin cap 
fibroatheroma (TCFA). Pathologic description of this type of plaque consist of a large necrotic 
core with an overlying thin and disrupted fibrous cap infiltrated by macrophages. The smooth 
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muscle cell components within the cap are absent or sparse. The thickness of such a thin 
fibrous cap is less than 65 μm11,12, so thin that it may not be identifiable even with IVUS.  
2.2 Shear stress 
While the entire coronary arteries are exposed to the systemic risk factors, atherosclerotic 
lesions frequently form at specific regions such as at the vicinity of side branches, along the 
outer wall of bifurcations, and on the inner wall of curved vessels.  An important local factor 
contributing to lesion formation in these locations is the effective endothelial shear stress 
(ESS)13, also called wall shear stress (WSS). Many studies confirmed the mechanistic role of 
low ESS in the development of atherosclerosis14-17. ESS is the tangential force derived from 
the friction of the flowing blood on the endothelial surface of the arterial wall and is 
proportional to the product of the blood viscosity (μ) and the spatial gradient of blood 
velocity at the wall.  
Viscosity can be measured or calculated from the measured hematocrit. Intracoronary blood 
flow can be calculated directly from the time required for the volume of blood contained 
within the vascular section to leave this section and be displaced by radio-opaque material 
during a contrast injection18.  
Normal ESS is pulsatile and unidirectional with magnitude that vary within a range of 15-70 
dyne/cm2 over the cardiac cycle17. Stone et al.19  published that plaque progression in 
minimally diseased coronary artery subsegments occurs almost exclusively in the areas of 
low ESS. At the same time, the vessels react on plaque progression by positive remodeling 
in the regions with a low ESS. However, the positive remodeling was also found in regions 
with high ESS with no plaque progression. It is important to keep in mind that imaging may 
be performed at a time when the ESS distribution, which leads to a specific plaque 
development, may have already been altered by plaque development at this or an adjacent 
location20. There are likely multiple stimuli and mechanistic pathway responsible for such 
positive remodeling. Low ESS contributes not only to plaque progression, but also increases 
the plaque vulnerability21. On the contrary, Helderman et al.22 found higher numbers of 
macrophages and higher metalloproteases activity in the region with high ESS. The question 
how the low ESS contributes to the plaque vulnerability has not been reliably answered yet. 
The mechanisms how low ESS influences local atherosclerosis likely includes activation of 
mechanoreceptors in the membrane of the endothelial cells and this signal activates or 
inhibits mechanosensitive genes. The atheroprotective genes are suppressed, whereas the 
pro-atherogenic genes are upregulated in the regions with a low ESS23.  
2.3 Atherosclerosis regression 
The atherosclerosis was thought to be a one-way process for many years. However, 
atherosclerosis regression was seen in autopsy findings from children, in angiographic 
studies and in studies conducted with IVUS.   
Fatty streaks in the aorta and the coronary arteries can been seen even in one year old 
children. These changes disappear at the age of four years and have an unquestionable 
relationship with breast feeding. Until now, it is not clear whether these findings reflect 
normal physiologic changes or whether they exhibit signs of premature atherosclerosis24.  
2.4 Angiographic studies 
Several angiographic studies assessing effects of statins on plaque progression have been 
published. The main target was the assessment of the minimal lumen diameter or mean 
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lumen diameter, differences between 0.03-0.08 mm were reported. It is questionable whether 
the angiography can precisely detect these negligible differences. Furthermore, these lumen 
changes are only indirect markers of plaque changes.  The overview of angiographic studies 
is provided in Table 1. 
 
 study  change of  MLD change of LDLc 
simvastatin SCAT25  - 0.07 mm / 3-5 years - 30% 
 MASS26 - 0.08 mm / 4 years - 31.4% 
lovastatin CCAIT27  - 0.05 mm / 2 years - 29% 
pravastatin REGRESS28 - 0.03 mm / 2 years - 25% 
 PLAC-129  - 0.03 mm / 1 year - 28 
fluvastatin LCAS30  - 0.028mm / 2.5 years - 22.5% 
Abbreviations: MLD = minimal lumen diameter, LDLc = low density lipoprotein cholesterol 
Table 1. Angiographic studies with statins. 
2.5 Studies with intravascular ultrasound - Methodology 
IVUS can precisely measure lumen, vessel and plaque volumes and therefore is an ideal tool 
for performing follow-up studies assessing changes of these volumes during lipid lowering 
therapy. Two different  IVUS designs can be used: Rotating element IVUS catheters 
operating at frequencies of 40 MHz, or electronic phased array catheters operating at a 
frequency of 20 MHz. Automatic motorized pullback is mandatory at a rate of 0.5 or 1.0 
mm/s for reliable three-dimensional imaging. There are several important factors which 
influence the  pullback quality31  
1. Adequate battery power in battery controlled pullback device. Using a battery at the 
end of its life produces a non-continuous pullback with a decreasing speed. 
2. Opening of the Y connector before starting the pullback. It causes small bleeding, but 
the movement of IVUS catheter is significantly smoother and thus more accurate. 
3. Straightening of the IVUS catheter before pullback, otherwise the speed of the IVUS 
catheter is not continuous/constant-speed at the beginning of the acquisition 
4. Even if the catheter is straightened, the pullback is the least accurate at the beginning of 
pullback and most accurate in the proximal part of image vessel. For this reason, it is 
recommended to start the IVUS pullback about 10 mm distal to the location of interest.  
Patients suitable for a plaque regression study are usually admitted for stable angina 
pectoris and undergo diagnostic angiography in the majority of cases.  Patients with normal 
findings on coronary angiography are excluded. For some research protocols, patients with 
a left main stenosis or a significant stenosis of all three coronary arteries may also be 
excluded because they will require revascularization and would not be suitable for a follow-
up study.  It is questionable whether patients with one significant stenosis should or should 
not be included. From our point of view, symptomatic patients with at least one significant 
stenosis should undergo revascularization and not be included in a medication-based 
plaque regression study.        
The ideal situation would be to perform IVUS in all three coronary arteries and to follow all 
identified plaques. However, such a design would be time consuming and complicated for 
the analysis and therefore, in a majority of trials, only one vessel is investigated at a time. 
www.intechopen.com
 
IVUS Role in Studies Assessing Atherosclerosis Development 
 
57 
The inclusion criterion is typically the identification of at least one location with the luminal 
stenosis > 20% by angiography, another useful criterion is may be plaque burden > 40% 
assessed by IVUS. In case of similar findings in more than one coronary artery during 
angiography, the artery with the longer plaque, or in case of several stenoses present in any 
single artery, the plaque with the most severe plaque burden should be selected for the IVUS 
analysis. The recommended segment length is greater than 30 mm with at least two clear 
landmarks (fiduciary points) in the proximal and distal parts of the analyzed segment. An 
obvious proximal landmark in the left coronary artery is the left main bifurcation. Further 
landmarks may be clearly defined side branches (conus branch or proximal atrial branch in the 
right coronary artery) or some recognizable calcifications. Despite the clear landmarks and 
identical conditions of the pullbacks during the baseline and follow-up, the baseline/follow-
up pullback lengths represented by frame counts will not be identical in the majority of cases. 
Possible reasons for this situation are technical errors while performing of pullback (low 
battery power, not straightened IVUS catheter before pullback, tight Y connector), or a slightly 
different trajectory of the IVUS catheters due to different positions of guide wires inside the 
coronary artery. Differences between the baseline and follow-up in the number of frames may 
be up to 15%, which is considered acceptable. Consequently, volumes may have to be 
calculated using the mean length between landmarks from the two studies31.  
Several automatic border detection software applications were developed to decrease the 
necessity of manual tracing. However, according to our experiences, careful inspection of all 
acquired frames and providing manual correction of almost all frames is frequently necessary 
during baseline/follow-up trials. The presence of calcium further complicates adventitial 
border detection. Heavily calcified lesions should be avoided for these types of trials due to a 
high risk of inaccuracy of volume measurements.  Using cross sectional analysis, a single 
deposit with an arc of calcium < 45 degrees or multiple small arcs of up to 180 degrees can be 
acceptable since they can be extrapolated. Another challenging part of a vessel when 
performing vessel wall border detection are regions with originating side branches. Several 
rules are recommended unless the branch is specifically modeled as such as described in the 
next paragraphs: The EEM contour should be interpolated to follow the main vessel cross-
sections immediately proximal and distal to the side branch and the lumen contour should be 
drawn on top of the EEM contour at the mouth of the side branch31.   
The parameters, which may be calculated include total atheroma volume (TAV) counted as 
(EEMCSA-Lumen CSA) and percent atheroma volume PAV counted as ((EEMCSA-Lumen CSA) 
/  EEMCSA)  x 100. Note that the presented simple calculation of TAV would not represent a 
true volume and would only be valid for comparisons if the inter-frame distance stays 
constant across all analyses. Therefore, TAV should be normalized with respect to the lesion 
length as described earlier: TAV / lesion length or normalized as (EEMCSA-Lumen CSA)  / 
(number of analyzed frames per patient ) and multiplied by  mean/median no. of analyzed 
frames in the population 31-33 . For expressing of changes between baseline and follow-up,- the 
absolute change of TAV or PAV (follow-up minus baseline) can be used and the percent 
change of TAV can be expressed as (TAVfollow up – TAV baseline / TAV baseline  x 100)31. The same 
approach to quantifying changes is possible for lumen volumes and vessel volumes.  
Another set of interesting and important parameters is describes the vessel remodeling.  For 
serial studies, it is recommended to calculate a remodeling index as (vessel volumefollow up – 
vessel volumebaseline), in which a positive value means positive remodeling and conversely a 
negative value represents negative remodeling. Furthermore, vessels with the positive 
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remodeling should be subdivided into expansive (over compensatory) where ΔEEM /  
Δatheroma is > 1 or incomplete  where ΔEEM / Δatheroma is between 0 and 1.031.  
More sophisticated assessment of plaque behavior is enabled by 3D reconstruction of 
vessels, which is done by fusion of angiography and IVUS.  This technique builds 
geometrically correct 3-D or 4-D (i.e., 3-D over all phases of the cardiac cycle) 
reconstructions of coronary arteries and computes quantitative indices of coronary lumen 
and wall morphology. The reconstructions may also serve as input for hemodynamic and 
morphologic analyses and allow for interactive visualization34 (Figure 1).   
 
 
Fig. 1. Plaque thickness assessment with local plaque thickness indicated by color coding on 
the lumen surface. 
In general, vessel curvature and torsion are derived from biplane (or a pair of single-plane) 
X-ray angiograms, and the cross-sectional information is obtained from IVUS. Thus, the 
resulting model accurately reflects the spatial geometry of the vessel and includes any 
accumulated plaque. Fusion leads to a 3-D or 4-D model, consisting of the lumen/plaque 
and media/adventitia contours oriented relative to the IVUS catheter. This may result in a 
surface mesh, which can include any branches segmented along with the main vessel to the 
extent visible in the IVUS (Figure 2). After proper meshing, this model is suitable for 
hemodynamic analyses. 
Morphologic analyses are performed following the resampling of the cross sections 
orthogonal to the vessel centerline, to eliminate distortions from the position of the IVUS 
catheter within the vessel. The quantitative results may annotate this resampled contour 
model, which is then used for visualization and further analysis.  
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Fig. 2. Meshing of the luminal surface obtained from a geometrically-correct 3D 
reconstruction depicting a side branch. 
The estimation of the absolute orientation of the IVUS frames in 3-D is a non-trivial issue 
and is usually resolved by using the angiographic lumen as a reference. The outline of the 
vessel lumen is visible in both angiographic projections when a small amount of contrast 
dye is injected. This is utilized to establish the orientation of the IVUS frames by finding 
their best fit with the angiographic outline. Using differential geometry, only the relative 
orientation changes from frame to frame can be established, the absolute orientation of the 
frame set yet needs to be determined at this stage. For this, a 3-D elliptical lumen outline is 
reconstructed from the angiograms and compared with the IVUS lumen outline, mapped 
into 3-D using an arbitrary initial orientation. This allows a non-iterative approach in which 
a single correction angle is calculated from an initial orientation and then applied to the 
entire frame set. The reconstructed vascular model provides 3-D locations for detected 
circumferential vertices (72 in our case) on both lumen/plaque and media/adventitia 
contours, oriented with respect to the IVUS catheter path. The blood flow through the 
coronary arteries is simulated and the wall shear stress distribution determined using 
computational fluid dynamics (CFD) methodology.  
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During the CFD, blood is treated as an incompressible, homogenous, and Newtonian fluid. 
Since the flow rate are difficult to be measured in each of the coronary arteries during data 
acquisition for each patient due to procedural limitations, a flow rate of 100 ml/min is 
sometimes assumed for all the coronary arterial segments employed in this analysis. 
Positive and negative wall shear stress values are determined at each circumferential lumen 
location and mapped onto the lumen vertices for each contour of the perpendicularly 
oriented 3-D model35 (Figure 3).  
 
 
Fig. 3. Shear stress assessment on a 3-D reconstructed coronary artery (the arrow indicates 
the direction of blood flow). 
2.6 Studies with intravascular ultrasound – Overview 
Studies with intravascular ultrasound have shown that disease progression can be stopped 
(GAIN1, REVERSAL2) or reversed (ASTEROID3, ESTABLISH4, COSMOS5) during lipid 
lowering therapy, as summarized in Table 2. The promising drug torcetrapib - inhibitor of 
cholesteryl ester transfer protein (CETP), which facilitates the transfer of cholesteryl ester 
from HDL cholesterol to LDL cholesterol and VLDL cholesterol  did not decrease percent 
atheroma volume. Furthermore, it increased the mortality (cardiovascular and all cause 
mortality) in ILLUMINATE trial36. The reason was increasing of blood pressure together 
with decreasing of potassium level (aldosteron like action). However, new CETP inhibitor 
without these effects is tested in preclinical trials.    
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study study design number 
of patient
results change of lipids 
Takagi.37 pravastatin 10mg 
vs. dietary 
stabilization 
25 decrease of plaque 
area in pravastatin 
group, no 
volumetric analysis 
LDLc: –27% vs.–9% 
HDLc: +29% vs. +17% 
Ishikawa 38 pravastatin 10-20 
mg  
40 relative change of 
TAV 20%  
LDLc : –23.5% 
HDLc : +9.3% 
GAIN1  atorvastatin 20-80 
mg vs. standard 
therapy,   
131 relative change of 
TAV 2.5% vs. + 
11.8% 
LDLc: -42% vs. -16% 
HDLc: +9% vs. + 12% 
REVERSAL2  80 mg 
atorvastatatin vs. 
40 mg pravastatin  
502 TAV: - 0.4mm3 vs. + 
5.1mm3, relative 
change of TAV: + 
4.1 vs. + 5.4% 
PAV: + 0.6% vs. + 
1.9%
LDLc: –46.3% vs. –25.2 
HDLc: +2.9 vs. +5.6%  
ASTEROID3 rosuvastatin 40 mg 349 PAV: -0.98%, TAV 
in worst 10 mm 
segment: -6.1mm3, 
9.1% relative 
changes and – 
14.7mm3 of 
normalized TAV
LDLc: -53.2% 
HDLc: +14.7% 
COSMOS5 rosuvastatin 2.5-
20mg  
126 relative change of 
TAV: -5.1% 
LDLc: -38.6% 
HDLc: +19.8% 
ESTABLISH4* atorvastatin vs. 
dietary treatment 
or cholesterol 
absorption 
inhibitors 
70 TAV: – 8.3mm3 vs. + 
4.2mm3 
relative changes of 
TAV -13.1% vs. + 8.7
LDLc: -43.8% vs. -3.6%  
HDLc: +2.4%  vs. +7.0% 
JAPAN-ACS39 pitavastatin 4gm 
vs. atorvastatin 
20mg 
252 TAV: – 8,2mm3 and 
– 10,6 mm3  
PAV: -5,7% vs. – 
6,3% 
patients with CAD 
and polyvascular 
extent of 
atherosclerosis had 
smaller regression 
compared to patients 
with CAD only40
LDLc -36.2% vs.– 35.8% 
HDLc +9.9% vs.+8% 
Jensen41 simvastatin 40mg 40 TAV or PAV are not 
available, authors 
found plaque 
regression
LDLc: –13,6% 
HDLc: +7% 
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study study design number 
of patient
results change of lipids 
Nissen42 recombinant 
ApoA-I Milano vs. 
placebo 
57 PAV -1.1% vs + 
0,14% 
not available 
REACH43 atorvatatin 10-
20mg vs. usual care 
58 TAV –1,4 mm3  vs. 
+7,6 mm3  
PAV – 1,95 % vs. 
+1,6% 
LDLc: –34% vs. 0% 
HDLc: -1% vs +1% 
ILLUSTRATE44 torcetrapib+ 
atorvastatin vs-. 
atorvastatin 
910 normalized TAV – 
9.4 vs- - 6.3mm3 , 
p=0.02 
PAV + 0.12% vs. + 
0.19%, p=0.72 
LDLc: –13.3% vs. +6.6% 
HDLc: +58.6% vs. +2.2% 
ACTIVATE32 pactimibe vs. 
placebo 
??? normalized TAV: -1.3 
mm3 vs. – 5.6 mm3  
PAV: +0.8% vs. 
+0.6%  
not available 
Nakayama45 pioglitazon 15mg 
vs. standard 
therapy  in diabetic 
patients 
26 TAV - 6.7 vs. 2.3 
mm3 
not available 
HEAVEN46 atorvastatin+ezetro
l vs. standard care 
89 PAV - 0.4% vs. + 
1.4%, p=0.01 
LDLc: -28.6% vs. – 1.9% 
HDLc: +4,5% vs. -1.3% 
Clementi47 Atorvastatin 80mg 
+ 30mg 
pioglitazone for 6 
month, no control 
group 
25 TAV -12.7  not available 
Nasu48 Fluvastatin vs. 
control according 
to LDLc 
80 TAV – 36.4 vs. + 
11.2 mm3, p<0.0001 
LDL -47.7% vs. -1.1 
HDL  +2.2% vs.  – 0.6% 
* patiens with ACS,  2 weeks after ACS with repeated IVUS after two weeks,  torcetrapib is an 
inhibitor for cholesteryl ester transfer protein , its development was stopped due to severe side effects 
(increase of blood pressure),  ACAT inhibitor (acyl–coenzyme A:cholesterol acyltransferase, which 
esterifies cholesterol in a variety of cells and tissues, CAD coronary artery disease 
Table 2. IVUS controlled progression / regression studies  
The changes of plaque volume were also examined in trials focusing on plaque composition. 
Decrease of plaque volume was found in HEAVEN46 (percent atheroma volume), IBIS 249 
(total atheroma volume) and studies done by Clementi47 (total atheroma volume) and Nasu47   
Only non-significant changes of plaque volume were found in studies done by Kawasaki50, 
Hong51. 
The changes of plaques composition during lipid-lowering therapy are not clear, because 
aforesaid studies found different results.  Decrease of fibrous (F) tissue and fibro-fatty (FF) 
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tissue and increase of necrotic core (NC) and calcification (DC) were found in HEAVEN and 
in IBIS 2 (non-darapladib arm) studies. Nasu found decrease of NC and FF and increase of F 
and DC tissues, Kawasaki published decrease of lipid and fibrous tissues, Clementi found 
increase of NC  and Hong increase of F and FF and decrease of NC and DC.  
However, there are a lot of substantial differences among these studies. They are comparing 
patients with or without lipid-lowering pretreatment, analyzing the whole examined 
segment or only the worst part of vessel and they are using different techniques for plaque 
composition assessment: VH-IVUS (Volcano Therapeutics), iMAP-IVUS (Boston Scientific), 
Integrated Backscatter IVUS and automated differential echogenicity52.  
2.7 Regresion of atherosclerosis as a surrogate study endpoint 
Every new drug or new therapeutic approach must demonstrate a significant clinical benefit 
in terms of a reduction in cardiovascular morbidity and mortality. Due to the high standard 
of care in modern era, it becomes more and more difficult to find significant differences 
between new and previous treatments. The assessment of plaque volume changes can be 
used as an alternative end point instead of “hard” clinical endpoints, because both 
angiographic53 and IVUS assessed plaque progression54,55  correlate with coronary events. 
This strategy enables to decrease a number of patients and duration of study56.    
3. Conclusion 
Studies with intravascular ultrasound confirmed the existence of atherosclerosis regression. 
This process can be started by high dose of lipid lowering drugs in combination with 
changing the life style, more recently also with ACAT inhibitors. To date, changes of plaque 
composition during development and regression of atherosclerosis have not been precisely 
described, and conflicting results continue being published in the literature.  
Recent regression/progression studies performed with intravascular ultrasound have a 
well-defined methodology, which must be fully respected to obtain reliable and comparable 
results. In addition to plain 2D IVUS studies, more comprehensive studies can be performed 
with high-tech vessel analysis in terms of 3D/4D reconstruction with a full-range of 
descriptions of the observed atherosclerotic processes including volume measurements, 
assessments of plaque composition and computing functional aspects such as the luminal 
shear stress. This concept allows a more complex assessment of atherosclerosis development 
and can reveal additional relationships among the morphologic and functional factors.    
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